上海赛伦生物技术股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及除董事长范志和先生外的全体董事保证本公告内容不存在 任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性依法承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 要求》、《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等有关规定，现将上海赛伦生物技术股份有限公司（以下简称"公司"）2023年 半年度募集资金存放与实际使用情况专项报告如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司 首次公开发行股票注册的批复》（证监许可【2022】204 号）的批准，公司获准 向社会公开发行人民币普通股 2,706 万股，每股面值为 1.00 元，每股发行价格 为 33.03 元，公司收到募集资金总额为 89,379.18 万元，扣除发行费用 10,886.82 万元，募集资金净额为 78,492.36 万元。上述募集资金已于 2022 年 3 月 4 日全部 到位，并存放于募集资金专项账户内。天职国际会计师事 ...

上海赛伦生物技术股份有限公司 独立董事关于第三届董事会第十五次会议 相关事项的独立意见 会对公司的正常经营产生重大不利影响。决策和审议程序符合《上市公司监管指 引第 2 号—上市公司募集资金管理和使用的监管要求》《上海证券交易所科创板 上市公司自律监管指引第 1 号—规范运作》等相关法律法规及公司《募集资金管 理制度》的规定，不存在变相改变募集资金投向和损害股东特别是中小股东利益 的情形。 综上，我们一致同意《关于部分募投项目延期的议案》。 第三届董事会第十五次会议决议通过《关于公司 2023 年半年度募集资金存 放与实际使用情况的专项报告的议案》的程序规范，符合《公司法》《证券法》 《上市规则》《公司章程》等有关规定。 综上，我们一致同意《关于公司 2023 年半年度募集资金存放与实际使用情 况的专项报告的议案》。 二、对《关于部分募投项目延期的议案》发表独立意见 本次部分募投项目延期是公司根据项目实施的实际情况做出的审慎决定，不 1 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上海证券交易所科创板股票上市规则》（以 下简称"《上市规则》" ...

第三届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会的召开情况 证券代码：688163 证券简称：赛伦生物 公告编号：2023-022 上海赛伦生物技术股份有限公司 上海赛伦生物技术股份有限公司（以下简称"公司"）第三届监事会第十一 次会议（以下简称"本次会议"）于 2023 年 8 月 28 日以现场结合通讯方式召开， 本次会议通知及相关材料已于 2023 年 8 月 17 日以书面方式送达公司全体监事。 公司监事 3 人，实际出席监事 3 人。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法 规、规范性文件和《上海赛伦生物技术股份有限公司章程》《上海赛伦生物技术 股份有限公司监事会议事规则》的有关规定，会议形成的决议合法、有效。 二、 监事会会议审议情况 经与会监事投票表决，审议通过了如下议案： 1、审议通过《关于公司 2023 年半年度报告及摘要的议案》 根据《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运 ...

重要内容提示： 会议召开时间：2023 年 5 月 29 日（星期一）下午 13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 证券代码：688163 证券简称：赛伦生物 公告编号：2023-016 上海赛伦生物技术股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩暨现金分红 说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 投资者可于 2023 年 5 月 22 日（星期一）至 5 月 26 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 dmb@serum-china.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海赛伦生物技术股份有限公司（以下简称"公司"）已于 2023 年 4 月 21 日发布公司 2022 年年度报告、2022 年度利润分配方案及 2023 ...

Financial Performance - The company's operating revenue for 2022 was CNY 174,221,005.91, a decrease of 16.52% compared to CNY 208,693,627.46 in 2021[20]. - The net profit attributable to shareholders for 2022 was CNY 64,135,803.84, down 16.14% from CNY 76,482,795.73 in the previous year[20]. - The net profit after deducting non-recurring gains and losses decreased by 35.71% to CNY 44,693,930.62 from CNY 69,513,945.85 in 2021[21]. - The net cash flow from operating activities fell by 26.41% to CNY 67,913,773.25 compared to CNY 92,288,488.20 in 2021[21]. - The company's total assets increased by 188.68% to CNY 1,163,066,774.97 at the end of 2022, up from CNY 402,891,055.95 at the end of 2021[21]. - The net assets attributable to shareholders grew by 203.36% to CNY 1,121,290,451.58 at the end of 2022, compared to CNY 369,629,071.96 at the end of 2021[21]. - Basic earnings per share decreased by 32.98% to CNY 0.63 in 2022 from CNY 0.94 in 2021[22]. - The company's revenue from the biopharmaceutical sector was approximately 174.22 million, with a gross margin of 83.77%, reflecting a slight increase of 0.18 percentage points compared to the previous year[112]. Dividend Distribution - The proposed profit distribution plan for 2022 is to distribute a cash dividend of RMB 7.50 per 10 shares (including tax), totaling RMB 81,165,000, which accounts for 126.55% of the net profit attributable to shareholders in 2022[5]. - In 2021, the company distributed cash dividends of RMB 97,398,000, which accounted for 127.35% of the net profit attributable to shareholders[190]. - The company has a well-defined decision-making process for dividend distribution, ensuring transparency and protection of minority shareholders' rights[191]. Research and Development - The R&D expenditure as a percentage of operating revenue was 8.87%, down 3.47 percentage points from 12.34% in 2021[22]. - The company has invested a total of ¥15,457,131.29 in R&D for the year, a decrease of 40% compared to ¥25,763,088.98 in the previous year[75]. - The company has applied for 6 new invention patents during the reporting period[33]. - The company is currently conducting clinical trials for the anti-viper venom serum, with a total investment of ¥1,600,000 and ¥1,065,400 invested to date[77]. - The company has developed proprietary technologies for toxin protein research, enabling effective analysis and purification of toxic components for the development of antitoxin drugs[65]. - The company is engaged in ongoing research and development of new technologies to enhance the quality of antivenoms and antitoxins, ensuring affordability and high production capacity[63]. Market Position and Strategy - The company is the only domestic producer and seller of snake antivenom, fulfilling emergency clinical needs in the public health sector[37]. - The company has a comprehensive competitive advantage in the field of antivenom and antitoxin drugs, supported by a rich R&D and technical team, GMP-certified production facilities, and a nationwide medical promotion team[36]. - The biopharmaceutical market in China is projected to reach RMB 1,319.8 billion by 2030, with a compound annual growth rate (CAGR) of 10.9% from 2023 to 2030[48]. - The company aims to enhance product promotion and coverage to reduce fatalities and disabilities caused by snakebites in China[53]. - The company is positioned to leverage its unique market position and advanced technology to expand its product offerings and market share[52]. Risk Management - The company has detailed various risks faced during operations in the report, emphasizing the importance of risk management[4]. - The report includes a forward-looking statement risk disclaimer, cautioning investors about potential uncertainties in future plans[6]. - The company faces risks related to price control or competition that could lead to a decrease in product prices and impact revenue growth[91]. - The company has a risk of product safety due to potential pathogens remaining in the plasma used for production, despite implementing screening and virus inactivation measures[90]. Corporate Governance - The company has established a standardized corporate governance structure in compliance with relevant laws and regulations, holding one shareholders' meeting and six board meetings during the reporting period[157]. - The company has implemented strict information disclosure practices, ensuring timely and accurate communication with investors and stakeholders[158]. - The company maintains independence from its controlling shareholder, ensuring no non-operational use of company funds[157]. - The company has established a comprehensive internal control system to ensure effective governance and risk management, covering various aspects including financial management and major investments[197]. Employee Management - The company emphasizes employee training, implementing various training programs to enhance skills and professional knowledge[187]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 5.6352 million RMB[174]. - The company has a competitive and equitable salary policy, aiming to motivate employees and enhance their performance[186]. - The number of R&D personnel has increased to 41, accounting for 13.31% of the total workforce, compared to 40 personnel and 13.56% in the previous year[80].

Financial Performance - The company's operating revenue for Q1 2023 was ¥23,955,839.36, representing a decrease of 3.80% compared to the same period last year[5] - The net profit attributable to shareholders was ¥3,015,115.00, down 23.86% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥1,283,466.89, a decline of 136.95%[5] - The basic and diluted earnings per share were both ¥0.03, reflecting a decrease of 25.00%[6] - The total operating profit for Q1 2023 was CNY 3,604,748, a decline of 18.7% from CNY 4,432,842 in the same period last year[20] - The total comprehensive income for Q1 2023 was CNY 3,015,115, reflecting a decrease from CNY 3,959,972 in the same quarter last year[21] - The net profit attributable to shareholders of the parent company for Q1 2023 was CNY 3,015,115, a decrease of 23.8% compared to CNY 3,959,972 in Q1 2022[21] Cash Flow - Cash flow from operating activities was -¥18,617,864.27, indicating a negative cash flow situation[6] - Cash flow from operating activities showed a net outflow of CNY 18,617,864, worsening from a net outflow of CNY 8,212,503 in Q1 2022[23] - Cash flow from operating activities in Q1 2023 was negative at -¥23,556,243.25, worsening from -¥12,895,985.53 in Q1 2022[32] - The company received cash from investment recovery amounting to ¥465,000,000.00 in Q1 2023, a substantial increase from ¥40,000,000.00 in Q1 2022[32] - The net cash flow from investment activities was negative at CNY -367,115,137, an improvement from CNY -707,982,663 in the previous year[24] - The net cash flow from investment activities was -$362.83 million, a decrease from -$705.89 million in the previous period[33] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,156,028,785.41, a decrease of 0.61% from the end of the previous year[6] - Total assets as of March 31, 2023, were RMB 1,156,028,785.41, slightly down from RMB 1,163,066,774.97 at the end of 2022[16] - Total liabilities decreased to RMB 31,723,218.83 from RMB 41,776,323.39, a reduction of 24.1%[17] - The total liabilities decreased to ¥16,768,864.59 in Q1 2023 from ¥27,268,328.38 in Q1 2022, indicating a significant reduction of 38.5%[27] - The company's total equity increased to RMB 1,124,305,566.58 from RMB 1,121,290,451.58, reflecting a growth of 0.2%[17] - The total equity as of Q1 2023 was ¥1,113,861,779.19, up from ¥1,109,800,236.71 in Q1 2022, reflecting a growth of 0.2%[27] Research and Development - The total R&D investment amounted to ¥3,275,505.96, which is 13.67% of the operating revenue, a slight decrease of 0.12 percentage points[6] - Research and development expenses for Q1 2023 were CNY 3,275,506, slightly down from CNY 3,435,324 in Q1 2022[20] - Research and development expenses for Q1 2023 were ¥3,275,617.75, slightly down from ¥3,435,324.49 in Q1 2022[29] Shareholder Information - The company reported a total of 8,017 common shareholders at the end of the reporting period[11] - The company's accounts receivable increased to ¥15,853,745.94 in Q1 2023 from ¥7,679,770.42 in Q1 2022, indicating a significant rise[26] - Accounts receivable rose to RMB 17,974,753.94 from RMB 7,679,770.42, indicating a significant increase of 134.5%[15] Strategic Focus - The company is focusing on new product development and market expansion strategies to improve future performance[19]

Financial Performance - The company's revenue for Q3 2022 was ¥71,224,053.26, representing a decrease of 1.15% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was ¥32,308,050.17, down 2.46% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥27,095,838.11, a decline of 14.90% compared to the previous year[5] - Total operating revenue for the first three quarters of 2022 was RMB 149,434,599.86, a decrease of 10.98% compared to RMB 167,970,821.17 in the same period of 2021[17] - The net profit for Q3 2022 was CNY 62,771,140.81, a decrease of 12.1% compared to CNY 72,158,230.66 in Q3 2021[18] - The total profit for Q3 2022 was CNY 73,163,332.95, a decrease of 12.5% compared to CNY 83,436,258.57 in the same quarter last year[18] - The net profit for the first three quarters of 2022 was CNY 63,106,277.36, down 9.06% from CNY 69,649,630.17 in the previous year[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,162,677,480.25, an increase of 188.58% compared to the end of the previous year[6] - The total assets of the company reached RMB 1,162,677,480.25, compared to RMB 402,891,055.95 at the end of 2021, indicating substantial growth[16] - The total liabilities increased to RMB 42,751,691.70 from RMB 33,261,983.99, marking a rise of 28.5%[15] - The total liabilities increased to CNY 27,146,500.32 in Q3 2022, compared to CNY 22,078,243.93 in Q3 2021, reflecting a growth of 23.5%[24] - The total equity rose significantly to CNY 1,107,720,567.08 in Q3 2022, compared to CNY 357,088,713.94 in Q3 2021, marking an increase of 210.4%[24] Shareholder Information - The equity attributable to shareholders at the end of the reporting period was ¥1,119,925,788.55, up 202.99% year-on-year[6] - The total number of ordinary shareholders at the end of the reporting period was 8,593[11] Research and Development - R&D expenses for the reporting period totaled ¥3,746,267.22, a decrease of 15.21% compared to the same period last year[6] - Research and development expenses decreased significantly to RMB 9,537,393.92 from RMB 14,967,192.02, a reduction of 36.2% year-over-year[17] - The company’s research and development expenses for the first three quarters of 2022 were CNY 9,675,989.56, down 46.6% from CNY 18,132,923.38 in the previous year[25] Cash Flow and Investments - The company's cash and cash equivalents as of September 30, 2022, were RMB 112,888,146.89, down from RMB 115,876,978.96 at the end of 2021[13] - Total cash inflow from investment activities was CNY 1,223,175,915.84, significantly higher than CNY 137,952,706.85 in the same period last year[20] - The net cash flow from investment activities was -CNY 753,906,332.87, worsening from -CNY 97,099,919.56 in the previous year[20] - The company reported a net cash outflow from investing activities of CNY -740,341,195.76 for the first three quarters of 2022, compared to CNY -85,121,985.45 in the previous year[30] Earnings Per Share - The basic earnings per share for Q3 2022 was ¥0.31, down 24.39% year-on-year[6] - Basic and diluted earnings per share for Q3 2022 were both CNY 0.63, down from CNY 0.89 in the same period last year[19] Financial Ratios - The weighted average return on net assets decreased by 6.57 percentage points for the reporting period, primarily due to an increase in net assets from stock issuance and a decrease in net profit[9] - The company’s total liabilities to equity ratio increased to 24.5% in Q3 2022, compared to 61.8% in Q3 2021, indicating improved financial leverage[24]

Financial Performance - The company reported a total revenue of 100 million RMB for the first half of 2022, reflecting a year-on-year increase of 15%[13]. - The company's operating revenue for the first half of 2022 was ¥78,210,546.60, a decrease of 18.46% compared to the same period last year[19]. - The net profit attributable to shareholders for the same period was ¥30,463,090.64, down 21.96% year-on-year[21]. - The net profit after deducting non-recurring gains and losses decreased by 38.04% to ¥22,149,544.43[21]. - The net cash flow from operating activities increased by 99.80% to ¥21,313,947.74, attributed to increased sales collections and reduced cash expenditures due to pandemic restrictions[21]. - The company's net assets at the end of the reporting period grew by 194.25% to ¥1,087,617,738.38, primarily due to funds raised from the initial public offering[21]. - Total assets increased by 181.03% to ¥1,132,259,195.67 compared to the end of the previous year[21]. - Basic earnings per share decreased by 33.33% to ¥0.32, while diluted earnings per share also fell by the same percentage[20]. - The proportion of R&D investment to operating revenue was 7.40%, a decrease of 3.60 percentage points compared to the previous year[20]. - The weighted average return on net assets decreased by 8.48 percentage points to 4.00%[20]. Market and Product Development - User data showed an increase in the number of customers by 20%, reaching a total of 50,000 active users[13]. - The company plans to launch two new products in Q3 2022, aiming to capture a larger market share in the immunotherapy sector[13]. - Future outlook includes a projected revenue growth of 25% for the full year 2022, driven by new product launches and market expansion efforts[13]. - Market expansion strategies include entering two new provinces in China by the end of 2022[13]. - The company specializes in the production of antivenom and antitoxin products, with a focus on snake antivenom, tetanus antitoxin, and rabies antiserum, holding a unique position in the domestic market[28]. - The company’s main product, the anti-snake venom serum, is the only effective treatment for snakebite poisoning in China, with no domestic competitors[29]. - The company has achieved fourth-generation production standards for its main products, including the horse tetanus immunoglobulin and anti-viper venom serum[27]. - The horse tetanus immunoglobulin is the only product in China that has obtained drug registration and production licenses, certified by GMP[31]. - The anti-rabies serum provides immediate neutralization of the rabies virus, recommended for high-risk exposure cases alongside vaccination[34]. Research and Development - The company is investing 10 million RMB in R&D for new technologies related to antibody production[13]. - The company achieved a total R&D investment of ¥5,791,126.70, a decrease of 45.10% compared to ¥10,548,709.30 in the same period last year[47]. - R&D investment accounted for 7.40% of total revenue, down from 11.00%, representing a decrease of 3.60 percentage points[47]. - The company published two SCI papers related to the preparation and identification of horse antiserum against sea snake venom, indicating ongoing collaboration with military medical institutions[45]. - The company has developed a high-efficiency virus inactivation technology to ensure the safety of antiserum products, enhancing the production process[43]. - The company has established a comprehensive immune technology database to optimize immunization protocols, resulting in higher antibody yield and reduced variability[42]. - The company has applied modern column chromatography purification technology, significantly reducing adverse reactions and serum sickness incidence in antiserum production[44]. - The company has not made significant changes to its core technologies during the reporting period, maintaining its proprietary techniques for effective antivenom production[44]. - The company reported a total of 6 new patent applications during the reporting period, with a cumulative total of 29 applications and 12 granted patents[46]. - The company’s research and development activities were impacted by the pandemic, causing delays and interruptions in some projects[49]. Risk Factors and Challenges - Risk factors identified include potential regulatory changes that could impact product approvals and market access[4]. - The company attributed the decline in revenue to the impact of COVID-19 on market activities, particularly affecting customers engaged in outdoor and field operations[21]. - The company faces risks related to product safety, price control, and increasing market competition, which could impact future performance[66]. - The company faced risks related to the single product structure, primarily relying on snake antivenom serum and tetanus immunoglobulin, which could adversely affect operations if sales or prices decline[67]. - The pandemic has negatively affected the company's production and market activities, particularly in outdoor and field operations, leading to reduced product demand[69]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by the Shanghai Qingpu District Ecological Environment Bureau[92]. - Main pollutants include waste gas and wastewater, with waste gas primarily consisting of VOCs, odor concentration, hydrogen sulfide, and oil smoke[93]. - The company has implemented various pollution control measures, including a recovery facility for ammonium sulfate and activated carbon purification devices[94]. - Wastewater is treated through a recovery process before being discharged into the Qingpu Second Wastewater Treatment Plant[95]. - The company has established an emergency response plan for environmental incidents, which has been filed with the environmental authorities[97]. - The company conducts regular environmental monitoring, ensuring that all pollutant discharge indicators meet standards[98]. - No administrative penalties were imposed on the company during the reporting period for environmental issues[99]. - The subsidiary, Sailun Dafeng, is not classified as a key pollutant discharge unit and manages its waste through biogas treatment for agricultural irrigation[100]. Shareholder Commitments and Governance - The company has committed to a lock-up period of 36 months for its shares held by major shareholders, including Zhao Aisan and Fan Zhihe, starting from the date of listing[103]. - Major shareholders, including Zhi Yuan Investment, have also agreed to a 36-month lock-up period for their shares following the company's IPO[108]. - If the company's stock price falls below the IPO price for 20 consecutive trading days within the first 6 months post-IPO, the lock-up period will automatically extend by an additional 6 months[106]. - The company has established a long-term commitment to maintain the integrity of its shareholding structure, with various commitments from shareholders and management to not transfer shares during the lock-up period[104]. - The company has outlined that any share reduction by major shareholders within two years post-lock-up must not be below the IPO price[109]. - The commitments made by shareholders and management are designed to ensure stability and confidence in the company's stock performance post-IPO[107]. - The company has a clear strategy to manage potential conflicts of interest among major shareholders, ensuring compliance with regulatory requirements[110]. - All commitments made by shareholders and management are legally binding, with potential legal consequences for any breaches[105]. - The company has emphasized the importance of transparency in shareholding changes during the lock-up period[106]. - The commitments are aimed at fostering investor trust and maintaining a stable market environment for the company's shares[104]. Cash Management and Fund Utilization - The company raised a total of 893,791,800.00 CNY from its initial public offering, with a net amount of 784,923,575.78 CNY after deducting issuance costs[170]. - As of the reporting period, the cumulative investment of raised funds amounted to 870,600.00 CNY, representing 0.22% of the total committed investment[172]. - The company utilized 361.25 thousand CNY of its own funds for the development of special new drugs and innovative technology projects during the period[170]. - The company approved the use of up to RMB 750 million of idle raised funds for cash management, with a usage period not exceeding 12 months[175]. - The company’s cash management strategy includes the purchase of financial products, with a remaining balance of RMB 418 million as of June 30, 2022[175]. - The company plans to maintain its cash management strategy while ensuring it does not affect the investment projects funded by the raised capital[175]. Future Outlook and Strategic Goals - The company plans to enhance its core competitiveness and sustainable profitability by increasing R&D investment and improving its sales network[129]. - The company acknowledges potential risks from regulatory changes, competitive products, and cost fluctuations, and will maintain good relationships with downstream customers[129]. - The company has committed to protecting the interests of minority shareholders and ensuring that any dilution of immediate returns is addressed through various measures[133]. - The company plans to distribute at least 20% of the distributable profits as cash dividends if conditions are met[140]. - In a mature stage without significant capital expenditure, cash dividends should constitute at least 80% of the profit distribution[143]. - In a mature stage with significant capital expenditure, cash dividends should constitute at least 40% of the profit distribution[143]. - In a growth stage with significant capital expenditure, cash dividends should constitute at least 20% of the profit distribution[143]. - Significant capital expenditure is defined as transactions involving assets totaling over 30% of the latest audited net assets[144]. - The board must consider the timing, conditions, and minimum ratios for cash dividends, requiring majority approval from both the board and supervisory board[141]. - The company will actively seek feedback from minority shareholders regarding dividend proposals[141].

Financial Performance - The company plans to distribute a cash dividend of RMB 9.00 per 10 shares, totaling RMB 97,398,000, which represents 127.35% of the net profit attributable to shareholders for 2021[5]. - The company has not yet achieved profitability since its listing[4]. - The company's operating revenue for 2021 was CNY 208,693,627.46, representing a 12.47% increase compared to CNY 185,562,793.03 in 2020[22]. - The net profit attributable to shareholders for 2021 was CNY 76,482,795.73, which is a 21.07% increase from CNY 63,173,802.30 in 2020[22]. - The net profit after deducting non-recurring gains and losses was CNY 69,513,945.85, reflecting a 23.06% increase from CNY 56,488,609.44 in 2020[22]. - The basic earnings per share for 2021 was 0.94 yuan, representing a 20.51% increase from 0.78 yuan in 2020[23]. - The weighted average return on equity increased to 23.08%, up 1.94 percentage points from 21.14% in 2020[23]. - The total assets at the end of 2021 were CNY 402,891,055.95, which is a 29.07% increase from CNY 312,148,232.39 at the end of 2020[22]. - The net assets attributable to shareholders increased by 25.47% to CNY 369,629,071.96 at the end of 2021, compared to CNY 294,606,422.89 at the end of 2020[22]. - The cash flow from operating activities for 2021 was CNY 92,288,488.20, a decrease of 6.17% compared to CNY 98,354,730.48 in 2020[22]. Research and Development - The company is focused on the development of new biological emergency rescue drugs under the ATS project[13]. - The company aims to enhance its production processes to achieve higher purity and quality in its products[13]. - The company is actively involved in the research and development of immunoglobulin products for various therapeutic applications[13]. - Research and development expenses accounted for 12.34% of operating revenue, an increase of 0.21 percentage points from the previous year[24]. - The total R&D investment for the year was approximately ¥25.76 million, an increase of 14.42% from the previous year, with R&D expenses accounting for 12.34% of total revenue[67]. - The company has developed core proprietary technologies for the safe and effective production of emergency treatment drugs, including toxin proteomics research and antigen purification technology[61]. - The company has established a structured governance framework to ensure effective decision-making and protect shareholder interests[137]. - The company has 12 ongoing research projects, including the development of antivenoms and immunoglobulins, with expected total investments ranging from 620.00 million RMB to 8,000.00 million RMB[69]. - The company has received 4 new invention patents during the reporting period, bringing the total number of granted patents to 12[65]. Market Position and Strategy - The company is committed to expanding its market presence and enhancing its product offerings in the biopharmaceutical sector[13]. - The biopharmaceutical market in China is expected to reach RMB 1,319.8 billion by 2030, with a compound annual growth rate (CAGR) of 10.9% from 2023 to 2030[48]. - The company is currently the only producer of antivenom serum and equine tetanus immunoglobulin in China, holding a unique market position[52]. - The company aims to become a leading enterprise in the field of biotoxin and biosafety drug development, focusing on the research and development of various types of antivenoms[38]. - The company has established a comprehensive marketing team covering the entire industry chain from research and development to production and sales[38]. - The company is focusing on strategic acquisitions to enhance its technology capabilities, targeting two potential companies by Q2 2024[151]. Operational Risks and Governance - The company has detailed various operational risks in the report, which investors should review[4]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a substantive commitment to investors[6]. - The company has not violated decision-making procedures for external guarantees[8]. - The company has not faced any issues with a majority of directors being unable to ensure the accuracy and completeness of the annual report[8]. - The company has established a comprehensive internal control system to ensure effective governance and management, covering major investments, related transactions, and external guarantees[174]. - The company has a solid governance structure involving the shareholders' meeting, board of directors, independent directors, supervisory board, and senior management[174]. Environmental and Social Responsibility - The company is classified as a key pollutant discharge unit, implementing various measures to manage waste gas and wastewater effectively[178]. - The company has established an environmental monitoring plan, ensuring that all pollution indicators meet the required standards through third-party testing[183]. - The company has implemented automatic online monitoring for wastewater discharge, ensuring real-time compliance with environmental standards[187]. - The company has actively improved product quality standards, adding new quality control projects for its anti-five-step snake venom serum[37]. - The company has established emergency response plans for environmental incidents, with regular training for employees to enhance crisis management capabilities[182]. - The company actively participates in social responsibility initiatives, including building a rescue network for snakebite patients[177]. Employee and Management - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to RMB 6.1287 million[154]. - The company has implemented a competitive and incentive-based salary policy to enhance employee motivation and performance[166]. - Employee benefits include free lunch, dormitory accommodations, free shuttle service, high-temperature allowances, annual health check-ups, holiday benefits, birthday benefits, and special benefits for female employees[167]. - The company emphasizes employee training across various aspects, including professional skills and knowledge, to enhance overall competency and retain talent[168]. - The company employed a total of 295 staff members, with 230 in the parent company and 65 in major subsidiaries[165]. Product Development and Quality Control - The company has established a comprehensive quality management system in compliance with GMP, ensuring product quality throughout the entire lifecycle[200]. - The company has a robust after-sales service system, including regular follow-ups and a user complaint management procedure[199]. - All sales drugs have obtained necessary registration certificates, with no administrative penalties due to quality issues reported during the period[200]. - The company has implemented a supplier evaluation and approval system to ensure quality and compliance of raw materials and components[199]. - The company has upgraded the production process of traditional tetanus antitoxin to improve purity and reduce adverse reaction rates, which is a necessary trend in the industry[60].

2022 年第一季度报告 证券代码：688163 证券简称：赛伦生物 上海赛伦生物技术股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | | 本报告期比上年 | | --- | --- | --- | --- | | | | | 同期增减变动幅 | | | | | 度(%) | | 营业收入 | | 24,903,036.81 | 12.04 | | 归属于上市公司股东的净利润 | | 3,959,971.69 | 15.87 | | 归属于上市公司股东的扣除非 | | 3,4 ...